Eli Lilly and Company (NYSE:LLY) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Eli Lilly and Company ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Eli Lilly and Company (NYSE:LLY) stock fell on Thursday morning after the pharmaceutical giant’s diabetes drug Mounjaro ...

Eli Lilly's Mounjaro diabetes drug has demonstrated superior performance over Trulicity in reducing heart attack and stroke ...

Eli Lilly's Mounjaro matched Trulicity in heart outcomes and showed added benefits on A1C, weight, kidney function, and ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

Eli Lilly's diabetes drug Mounjaro demonstrated superior efficacy to its predecessor Trulicity in reducing heart attack and ...

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...